Table 1.
Characteristics of patients diagnosed with stage I-III breast cancer in 2011 (N = 25,535).
| Characteristics | NHW (N = 18,402), % | NHB (N = 3,497), % | Hispanics (N = 3,636), % |
|---|---|---|---|
| All | 72.1 | 13.7 | 14.2 |
| Age | |||
| < 50 | 19.4 | 28.6 | 31.9 |
| 50–59 | 24.3 | 29.1 | 24.5 |
| 60–69 | 28.5 | 23.0 | 21.9 |
| 70–79 | 18.1 | 13.2 | 14.6 |
| ≥80 | 9.8 | 6.1 | 7.1 |
| P-value* | < 0.0001 | < 0.0001 | |
| Insurance | |||
| Private | 58.5 | 48.1 | 46.6 |
| Medicare/other public | 29.2 | 22.9 | 19.4 |
| Medicaid | 6.3 | 20.3 | 18.8 |
| None | 2.1 | 6.4 | 11.5 |
| Unknown | 3.4 | 2.4 | 3.7 |
| P-value* | < 0.0001 | < 0.0001 | |
| Residence | |||
| Urban | 52.1 | 67.3 | 78.6 |
| Rural | 10.1 | 6.2 | 2.5 |
| Urban/rural mixed | 37.8 | 26.5 | 18.9 |
| P-value* | < 0.0001 | < 0.0001 | |
| Census tract-poverty | |||
| < 10% | 53.1 | 23.7 | 30.2 |
| 10–19.99% | 33.3 | 32.0 | 34.9 |
| ≥ 20% | 13.5 | 44.3 | 34.9 |
| P-value* | < 0.0001 | < 0.0001 | |
| Subtype | |||
| HR + /HER− | 66.7 | 53.5 | 59.6 |
| HR + /HER2 + | 9.0 | 9.6 | 9.9 |
| HR−/HER2− | 10.2 | 21.2 | 11.7 |
| HR−/HER2 + | 3.5 | 4.8 | 5.3 |
| Unknown | 10.5 | 10.9 | 13.5 |
| P-value* | < 0.0001 | < 0.0001 | |
| AJCC stage | |||
| I | 55.1 | 41.9 | 45.1 |
| II | 33.3 | 40.6 | 39.3 |
| III | 11.6 | 17.4 | 15.6 |
| P-value* | < 0.0001 | < 0.0001 | |
| Bloom-Richardson grade | |||
| Low | 22.1 | 13.0 | 11.2 |
| Medium | 32.3 | 26.3 | 18.8 |
| High | 20.2 | 30.6 | 18.1 |
| Unknown | 25.4 | 30.1 | 52.0 |
| P-value* | < 0.0001 | < 0.0001 | |
| Tumor size | |||
| ≤ 0.5 cm | 9.0 | 7.9 | 7.7 |
| 0.6–1.0 cm | 18.5 | 12.7 | 14.9 |
| 1.1–2.0 cm | 36.4 | 31.1 | 32.6 |
| 2.1–5.0 cm | 29.4 | 36.4 | 35.7 |
| ≥5.1 cm | 6.0 | 10.9 | 8.1 |
| Unknown | 0.8 | 1.1 | 1.1 |
| P-value* | < 0.0001 | < 0.0001 | |
| Lymph node involvement | |||
| Negative | 62.4 | 55.1 | 55.9 |
| Positive | 27.0 | 34.9 | 33.4 |
| Unknown | 10.6 | 10.1 | 10.6 |
| P-value* | < 0.0001 | < 0.0001 | |
| Charlson comorbidity index | |||
| 0 | 83.6 | 77.0 | 85.2 |
| 1 | 12.6 | 16.8 | 11.4 |
| ≥2 | 3.8 | 6.2 | 3.4 |
| P-value* | < 0.0001 | 0.05 | |
| Participating states | |||
| Alaska | 1.0 | 0.1 | 0.3 |
| California | 7.4 | 4.1 | 6.4 |
| Colorado | 10.7 | 1.7 | 7.3 |
| Florida | 10.8 | 16.5 | 33.0 |
| Idaho | 3.9 | 0.0 | 0.6 |
| Louisiana | 8.3 | 19.2 | 1.3 |
| North Carolina | 22.3 | 31.2 | 3.0 |
| New Hampshire | 4.6 | 0.1 | 0.4 |
| Rhode Island | 3.0 | 0.5 | 1.2 |
| Texas | 28.2 | 26.6 | 46.4 |
| P-value* | < 0.0001 | < 0.0001 |
Abbreviations: NHW: non-Hispanic white; NHB: non-Hispanic black; AJCC: American Joint Committee on Cancer; HR: hormone receptor; HER2: human epidermal growth factor receptor 2.
*
P-values were calculated from the comparisons with Non-Hispanic white.